bpc 157 safety adverse effects toxicity BPC-157 – No Proof Required! | Office for Science and Society The Human Lab Rats Injecting
Description
PMID: 40573323
When CJC-1295, Ipamorelin, Kisspeptin-10, or other compounds become available through legitimate compounding channels after completing the PCAC process, we will evaluate the clinical evidence and offer them as part of comprehensive treatment plans
These goals are in direct opposition
All other drugs with a positive effect in neurological symptoms in a preclinical trial in SCA3 rodent models (and which have not been tested in SCA3 patients) are not used in the clinic for other disorders
